Oct 21, 2026 07:04AM
Oct 21, 2026 07:01AM
Oct 14, 2026 07:01AM
Oct 14, 2026 07:01AM
Oct 5, 2026 07:01AM
Sep 30, 2026 07:19AM
Sep 29, 2026 07:01AM Invivyd's VYD2311 shows fewer side effects than mRNA COVID vaccine
Sep 29, 2026 07:01AM
Sep 8, 2026 07:01AM
Sep 1, 2026 07:02AM
Sep 1, 2026 07:01AM
Aug 18, 2026 06:42AM
Aug 13, 2026 04:05PM
Aug 4, 2026 07:01AM Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) 
Jul 8, 2026 06:43AM
Jul 6, 2026 07:06AM
Jul 6, 2026 07:01AM
Jul 2, 2026 07:01AM
Jun 29, 2026 07:00AM
Jun 16, 2026 07:01AM
Jun 16, 2026 07:01AM Invivyd Announces Completion of Enrollment in Phase 3 LIBERTY Trial Evaluating VYD2311 Antibody Versus mRNA COVID-19 Vaccine
Jun 9, 2026 07:01AM
Jun 9, 2026 07:01AM
Jun 3, 2026 07:01AM
Jun 1, 2026 07:02AM
Jun 1, 2026 07:01AM
May 27, 2026 07:01AM
May 14, 2026 07:01AM Invivyd Reports First Quarter 2026 Financial Results and Recent Business Highlights
May 11, 2026 07:01AM
May 11, 2026 07:01AM
May 7, 2026 07:01AM
May 5, 2026 07:01AM
Apr 20, 2026 07:01AM
Apr 9, 2026 07:03AM
Apr 9, 2026 07:01AM Invivyd Announces REVOLUTION Program Progress and Advancement of Novel, Potential First- and Best-in-Class Measles Monoclonal Antibody Candidate VMS063 for Treatment and Prevention of Measles
Apr 6, 2026 07:01AM
Mar 30, 2026 04:05PM
Mar 5, 2026 07:03AM
Mar 5, 2026 07:01AM
Mar 5, 2026 07:01AM
Mar 2, 2026 04:10PM
Mar 2, 2026 04:01PM Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Feb 24, 2026 07:01AM
Feb 4, 2026 07:09AM
Feb 3, 2026 07:01AM
Feb 3, 2026 07:01AM
Jan 22, 2026 07:01AM
Jan 22, 2026 07:01AM
Jan 20, 2026 07:01AM Invivyd plans phase 2 trial of VYD2311 for long COVID treatment
Jan 20, 2026 07:01AM

335,387 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All